Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADXS11-001 |
Synonyms | |
Therapy Description |
Lovaxin C (ADXS11-001) is an attenuated Listeria monocytogenes expressing HPV 16 E7 which may induce cytotoxic immune response against tumor cells expressing HPV 16 E7 (PMID: 25483687). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADXS11-001 | Lovaxin C | Lovaxin C (ADXS11-001) is an attenuated Listeria monocytogenes expressing HPV 16 E7 which may induce cytotoxic immune response against tumor cells expressing HPV 16 E7 (PMID: 25483687). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02164461 | Phase Ib/II | ADXS11-001 | ADXS11-001 High Dose HPV+ Cervical Cancer | Completed | USA | 0 |
NCT02002182 | Phase II | ADXS11-001 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | Completed | USA | 0 |
NCT02291055 | Phase Ib/II | Durvalumab ADXS11-001 | Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer | Terminated | USA | 0 |
NCT02399813 | Phase Ib/II | ADXS11-001 | Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum | Completed | USA | 0 |
NCT02853604 | Phase III | ADXS11-001 | Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) | Terminated | USA | POL | ESP | CAN | BRA | ARG | 8 |